A combined analysis of blood tests to measure three biomarkers linked to higher risk of cardiovascular disease-lipoprotein a (Lp(a)), remnant cholesterol and high-sensitivity C-reactive protein (hsCRP)-may help identify high-risk individuals earlier and guide more personalized prevention strategies, according to a preliminary study to be presented at the American Heart Association’s Scientific Sessions 2025.